The U.S. Food and Drug Administration took action this week that should make it easier to get a lower cost near-copy of a brand-name insulin, Lantus, at the pharmacy. Semglee has been approved as both biosimilar to, and interchangeable as a substitute for Lantus, a widely used long-acting insulin. Biosimilar drugs are not […]
